CLINICAL TRIALS PROFILE FOR SULFAMETHOPRIM

All Clinical Trials for SULFAMETHOPRIM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT04502095 ↗	Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy	Recruiting	National Cancer Institute (NCI)	Phase 4	2020-08-04	This trial investigates whether a one-month course of preventative (prophylactic) antibiotics helps to reduce urinary tract infections after robot-assisted surgery to remove all of the bladder as well as nearby tissues and organs (radical cystectomy). Urinary tract infections are a common occurrence after robot-assisted radical cystectomy. Antibiotics such as trimethoprim-sulfamethoxazole or nitrofurantoin may prevent or control infections in patients with urinary tract infection and may help improve their response to radical cystectomy. Information gained from this study may help researchers to predict patient complications and identify better ways to manage these complications.
NCT04502095 ↗	Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy	Recruiting	Roswell Park Cancer Institute	Phase 4	2020-08-04	This trial investigates whether a one-month course of preventative (prophylactic) antibiotics helps to reduce urinary tract infections after robot-assisted surgery to remove all of the bladder as well as nearby tissues and organs (radical cystectomy). Urinary tract infections are a common occurrence after robot-assisted radical cystectomy. Antibiotics such as trimethoprim-sulfamethoxazole or nitrofurantoin may prevent or control infections in patients with urinary tract infection and may help improve their response to radical cystectomy. Information gained from this study may help researchers to predict patient complications and identify better ways to manage these complications.

Clinical Trial Conditions for SULFAMETHOPRIM

Condition Name

Condition Name for SULFAMETHOPRIM
Intervention	Trials
Bladder Carcinoma	1
Lymphoma	1
Refractory Bladder Carcinoma	1
Urinary Tract Infection	1

Condition MeSH

Condition MeSH for SULFAMETHOPRIM
Intervention	Trials
Urinary Bladder Neoplasms	1
Infections	1
Infection	1
Communicable Diseases	1

Clinical Trial Locations for SULFAMETHOPRIM

Trials by Country

Trials by Country for SULFAMETHOPRIM
Location	Trials
United States	3

Trials by US State

Trials by US State for SULFAMETHOPRIM
Location	Trials
New York	1
Texas	1
Florida	1

Clinical Trial Progress for SULFAMETHOPRIM

Clinical Trial Phase

Clinical Trial Phase for SULFAMETHOPRIM
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for SULFAMETHOPRIM
Clinical Trial Phase	Trials
Completed	1
Recruiting	1

Clinical Trial Sponsors for SULFAMETHOPRIM

Sponsor Name

Sponsor Name for SULFAMETHOPRIM
Sponsor	Trials
National Cancer Institute (NCI)	2
M.D. Anderson Cancer Center	1
Roswell Park Cancer Institute	1

Sponsor Type

Sponsor Type for SULFAMETHOPRIM
Sponsor	Trials
Other	2
NIH	2

Last updated: July 28, 2026

Sulfamethoprim clinical trials update, market analysis, and 2026–2035 projection

Sulfamethoprim is a fixed-dose combination of sulfamethoxazole plus trimethoprim. As of this update, the publicly available evidence set is insufficient to produce a complete, source-cited clinical-trials calendar and market forecast with defensible, company- and jurisdiction-specific claims at Bloomberg-grade precision.

What is sulfamethoprim and how is it positioned clinically?

Sulfamethoprim is a systemic antibacterial used primarily where sulfonamide plus diaminopyrimidine coverage is appropriate. Clinically, it is prescribed for susceptible bacterial infections and as an antimicrobial prophylaxis option in defined patient populations, depending on local labeling and resistance patterns.

Which dosage forms exist in practice?

Common marketed forms for sulfonamide-trimethoprim combinations typically include:

• Oral tablets
• Oral suspensions

What drug–drug interactions matter for uptake?

Operationally, the combination’s interaction profile is driven by:

• Sulfonamide-associated risks (including hypersensitivity)
• Trimethoprim’s effect on folate metabolism and renal handling

These factors influence prescribing guidelines and contribute to conservative adoption in high-risk comorbidity settings.

What clinical trials are currently updating for sulfamethoprim?

No complete, source-citable, up-to-date clinical-trials dataset is available in the provided information context to support:

• Active trials (phase, enrollment, start/completion dates)
• Readouts (primary endpoints, effect sizes)
• Geographic footprint (US/EU/ROW)
• Sponsorship (companies/academic groups)

How does sulfamethoprim’s trial pipeline compare with alternatives?

Sulfamethoprim competes indirectly against:

• Other sulfonamide combinations
• Trimethoprim monotherapy
• Broader-spectrum oral antibiotics used in outpatient settings
• Local guideline-driven choices shaped by resistance and stewardship policies

A comparative pipeline analysis requires an auditable trial list by alternative products and a matched timeline.

What is the market size and growth outlook for sulfamethoprim?

A defensible market model needs:

• Prior-year global and major-region sales by branded and generic segments
• Unit trends (tablets and suspension volumes)
• Pricing dynamics (post-loss-of-exclusivity trajectory)
• Supply and manufacturing constraints
• Regulatory and reimbursement changes

No source-cited market baseline is present in the provided information context to compute:

• 2026–2035 CAGR
• Segment splits (brand vs generic, pediatrics vs adult, prophylaxis vs treatment)
• Forecast sensitivities (resistance, formulary inclusion)

What pricing, reimbursement, and generic dynamics drive sulfamethoprim demand?

For older combination antibiotics, market behavior is usually driven by:

• Generic penetration and price erosion
• Formulary positioning in hospitals and outpatient plans
• Pediatric prescribing patterns (where suspensions matter)
• Stewardship and guideline adherence

A forecast must link demand to specific reimbursement regimes and local guideline prevalence, which is not available in the supplied context.

What competitive landscape exists for sulfamethoprim?

The competitively relevant set typically includes:

• Generic sulfamethoxazole-trimethoprim manufacturers across major markets
• Branded combinations where still present
• Alternative antibiotics displacing use for specific indications

A structured competitive mapping requires a source-cited list of key manufacturers by region and their latest approvals and launches.

What is the 2026–2035 market projection for sulfamethoprim?

A credible projection requires at minimum:

• A forecast starting point (latest annual sales with source citations)
• Historical volume and pricing series
• Expected demand drivers (guideline trends, resistance epidemiology, payer behavior)
• Expected supply constraints and manufacturing capacity
• Regulatory changes affecting availability

The provided information does not include these anchor inputs, so no complete and accurate projection can be produced.

Key Takeaways

• Sulfamethoprim is a fixed-dose antibiotic combination (sulfamethoxazole + trimethoprim) with ongoing clinical use, but a source-cited, up-to-date clinical-trials update cannot be produced from the provided information context.
• A defensible global market sizing and 2026–2035 projection cannot be produced without an auditable sales baseline and forecast inputs.
• The next actionable step for an investing, licensing, or litigation workflow is to build an Orange Book style dossier (where applicable), trial registry extraction, and sales baseline, then model volume and price drivers by region.

FAQs

Which indications most influence sulfamethoprim prescribing volume?

Prescription volume typically correlates with common outpatient infection categories and prophylaxis use where guideline-concordant.

Will resistance trends increase or decrease sulfamethoprim use?

Resistance to sulfonamide-trimethoprim can reduce effective use, but net impact depends on regional antibiograms and guideline thresholds.

Is sulfamethoprim more used in pediatrics or adults?

Market mix often depends on availability of pediatric-appropriate suspensions and pediatric guideline inclusion.

What affects short-term supply stability for sulfamethoprim?

APIs, antibiotic manufacturing capacity, and regulatory enforcement actions can affect short-term availability.

How do generic substitutions impact sulfamethoprim revenue?

Generic substitution usually compresses pricing and can shift value toward volume and low-cost supply chains.

References

1. (No cited sources were provided in the input context.)